Brainomix Stroke AI Software Hailed as ῾Revolutionary,' Helping More Patients Fully Recover

OXFORD, England and CHICAGO, Sept. 3, 2025 /PRNewswire/ -- Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has garnered widespread media attention¹ this week following a renewed focus on the impact of its Brainomix 360 Stroke technology to improve recovery rates for stroke patients.

A study published by the Royal Berkshire Hospital demonstrated that Brainomix software tripled the number of stroke patients achieving functional independence, from 16% to 48%. Additional data from the largest real-world evaluation of stroke AI imaging showed that Brainomix 360 Stroke was associated with a more than 50% increase in mechanical thrombectomy, a life-changing stroke treatment.

Brainomix 360 Stroke is a comprehensive platform powered by highly advanced AI algorithms, supporting clinicians by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients in both specialist and general hospitals.

David Hargroves, the NHS Clinical Director for Stroke, said: "This AI decision support technology is revolutionizing how we help people who have been affected by stroke. It is estimated a patient loses around 2m brain cells a minute at the start of a stroke, which is why quick diagnosis and treatment is so critical. AI decision support software provides real-time interpretation of patients' brain scans – supporting expert doctors and other NHS staff to make faster treatment decisions."

Dr Michalis Papadakis, CEO and Co-Founder at Brainomix, said: "Brainomix is helping clinicians every day improve the level of care they can deliver to stroke patients in the UK and worldwide. We are delighted to see a focus on the unique and powerful impact that our technology is having on patient outcomes, validated by an expanding base of published, real-world evidence."

Brainomix is widely recognised as one of the UK's most successful AI healthcare companies, having developed its technology through commercial scale up to market launch, and having secured a number of successful partnerships with NHS England and The Health Innovation Network.

Brainomix 360 Stroke has been deployed widely across the UK and Europe, where it is the established market leader, and in the United States, where it has been validated by a number of world-class stroke institutions and exhibiting a similar clinical impact on stroke care.

¹ The Times, The Guardian, The Telegraph, The Daily Mail, The Independent, The Sun, The Mirror

Notes to Editors

About Brainomix

Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spinout from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 20 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.

Contacts

Jeff Wyrtzen, Chief Marketing Officer
jwyrtzen@brainomix.com
T +44 (0)1865 582730

Media Enquiries

Charles Consultants
Sue Charles
Sue@charles-consultants.com
M +44 (0)7968 726585

Image - https://mma.prnewswire.com/media/2763605/Brainomix_360_Stroke.jpg